Sound Pharma Announces Positive Phase 3 Results for the Treatment of Menieres Disease with SPI-1005

This is a Phase 3 study, so the next step is FDA approval and commecialisation.

Sound Pharma Announces Positive Phase 3 Results for the Treatment of...38

SEATTLE — Sound Pharmaceuticals is pleased to announce that the pivotal Phase 3 clinical trial involving SPI-1005, a novel anti-inflammatory...